Originally published In Press as doi:10.1074/jbc.M001021200 on March 28, 2000
J. Biol. Chem., Vol. 275, Issue 29, 22147-22156, July 21, 2000
Guanylyl Cyclase Activity Associated with Putative Bifunctional
Integral Membrane Proteins in Plasmodium falciparum*
Daniel J.
Carucciabcd,
Adam A.
Witneyabce,
David K.
Muhiaabf,
David C.
Warhurstag,
Pauline
Schaaph,
Marcel
Meimahi,
Ji-Liang
Liaj,
Martin C.
Taylora,
John M.
Kellya, and
David A.
Bakerak
From the a Department of Infectious and Tropical
Diseases, London School of Hygiene and Tropical Medicine, Keppel
Street, London, WC1E 7HT, United Kingdom, the h Department
of Biochemistry, University of Dundee, MSI/WTB Complex, Dow Street,
Dundee DD1 5EH, United Kingdom, and the i Cell Biology
Section, Institute for Molecular Plant Sciences, University of
Leiden, Wassenaarseweg, 64, 2333AL Leiden, The Netherlands
Received for publication, February 8, 2000, and in revised form, February 29, 2000
 |
ABSTRACT |
We report here that guanylyl cyclase
activity is associated with two large integral membrane proteins
(PfGC
and PfGC
) in the human malaria parasite Plasmodium
falciparum. Unusually, the proteins appear to be bifunctional;
their amino-terminal regions have strong similarity with P-type
ATPases, and the sequence and structure of the carboxyl-terminal
regions conform to that of G protein-dependent adenylyl
cyclases, with two sets of six transmembrane sequences, each followed
by a catalytic domain (C1 and C2). However, amino acids that are
enzymatically important and present in the C2 domain of mammalian
adenylyl cyclases are located in the C1 domain of the P. falciparum proteins and vice versa. In addition, certain key residues in these domains are more characteristic of
guanylyl cyclases. Consistent with this, guanylyl cyclase activity was
obtained following expression of the catalytic domains of PfGC
in
Escherichia coli. In P. falciparum, expression
of both genes was detectable in the sexual but not the asexual blood
stages of the life cycle, and PfGC
was localized to the
parasite/parasitophorous vacuole membrane region of gametocytes. The
profound structural differences identified between mammalian and
parasite guanylyl cyclases suggest that aspects of this signaling
pathway may be mechanistically distinct.
 |
INTRODUCTION |
The life cycle of the human malaria parasite Plasmodium
falciparum is complex with several stages that differ at both the morphological and biochemical levels. Mosquito transmitted sporozoites migrate to the liver where they undergo asexual multiplication within
hepatocytes. Liver forms are then released into the bloodstream where
they invade red blood cells. A small proportion of the erythrocytic forms develop into gametocytes, precursors of male and female gametes.
When gametocytes are taken up by a mosquito during a bloodmeal, they
must first emerge from the red blood cells as gametes before
fertilization occurs in the midgut, prior to completion of the insect
stages of the parasite life cycle. The emergence of eight motile male
gametes from a red blood cell is known as exflagellation. Recent work
(1) has identified xanthurenic acid, a metabolite of tryptophan, as a
putative in vivo gametocyte-activating factor. In both
P. falciparum and Plasmodium berghei there is evidence that cyclic GMP may be involved in the development and emergence of male gametes (2). The parasite signaling pathways involved
in these processes remain to be elucidated.
Two key components of signal transduction pathways are adenylyl cyclase
(AC)1 and guanylyl cyclase
(GC), enzymes that catalyze the conversion of ATP and GTP to cAMP and
cGMP, respectively. Membrane-associated mammalian ACs are activated
indirectly following interaction of a ligand with a separate receptor.
This in turn binds to an intracellular heterotrimeric GTP-binding
protein (G protein). Subunits of the activated G protein then interact
with AC stimulating the synthesis of cAMP, which activates
cAMP-dependent protein kinase (PKA). PKA phosphorylates a
number of proteins; its final destination is often the nucleus where it
activates transcription factors, thereby changing the pattern of gene
expression. In mammals, nine distinct membrane-localized ACs have so
far been characterized (3). They conform to the same basic structure
comprising two sets of six hydrophobic transmembrane domains, each of
which is followed by a cytoplasmic catalytic region termed C1 and C2,
respectively. The amino-terminal portions (C1a and
C2a) are homologous with each other and between species
(4). Guanylyl cyclase exists in two main forms. The receptor form (with
a single membrane-spanning domain) binds directly to an extracellular
ligand leading to activation and production of intracellular cGMP. The
soluble, cytosolic form of the enzyme is activated by nitric oxide in
the presence of heme (reviewed in Ref. 5). GCs have a variety of roles
in higher organisms, for example in photoreceptor signal transduction
(reviewed in Ref. 6). GCs have also been identified in several lower organisms including protozoans such as Dictyostelium (7),
Paramecium, and Tetrahymena (8, 9). In sea
urchins, a membrane-bound GC found on the surface of sperm can act as a
receptor for peptides released by the eggs, which influence sperm
chemotaxis (reviewed in Ref. 10). cGMP often exerts its function by
binding to and activating cGMP-dependent protein kinase,
which phosphorylates and regulates the activity of a number of specific proteins.
As part of an investigation of the role of cyclic nucleotides in signal
transduction in the malaria parasite, we have isolated two genes from
P. falciparum that encode integral membrane proteins. These
proteins are unusual in that they appear to be bifunctional. The
amino-terminal regions have strong similarity to P-type ATPases, and
the carboxyl-terminal regions, including domains with GC activity, conform to a structure normally associated with G
protein-dependent ACs.
 |
EXPERIMENTAL PROCEDURES |
Parasite Culture--
P. falciparum clones 3D7A (11),
T996 (12), and strain K1 (12) were cultured in flasks with RPMI 1640 medium supplemented with 25 mM Hepes, 0.1 mM
hypoxanthine, 10% human serum (A+) as described previously (13).
Cultures contained A+ human red blood cells at a 10% hematocrit. Large
scale parasite preparations of clone 3D7A were produced using a
semi-automated continuous flow apparatus. Gametocytes (stages III-V)
were harvested and purified by Percoll gradient centrifugation
(13).
Isolation of Nucleic Acids--
Genomic DNA was isolated from
109 mixed asexual erythrocytic stage parasites according to
standard procedures (14). Briefly, the parasites were first released
from red blood cells by treatment with 0.1% saponin in
phosphate-buffered saline. The cell pellet was then washed twice with
phosphate-buffered saline and incubated in a solution containing 100 µg ml
1 proteinase K, 0.5% SDS, 100 mM
NaCl, 10 mM Tris, pH 8.0, 25 mM EDTA at
37 °C for 16 h. DNA was further purified by phenol extraction and ethanol precipitation. Total RNA was isolated from 5 × 108 gametocytes (mainly stages III-V) or mixed asexual
erythrocytic stage parasites by lysis with 4 M guanidine
thiocyanate and CsCl centrifugation (15).
Amplification of PfGC
Sequences by PCR--
A 220-bp fragment
of the PfGC
gene was isolated from genomic DNA (strain
K1) by PCR using the degenerate primers DC1 (sense) and MS2
(antisense), which were derived from conserved regions of AC/GC genes
from diverse species. The reactions (50 µl) were carried out in 10 mM Tris, pH 8.8, 50 mM KCl, 0.5-5
mM MgCl2, and 1% Triton X-100 with 1 µM of each primer, 200 µM dNTP mix, 1 unit
of Biotaq enzyme (Bioline) and 1-50 ng of template DNA. To minimize
nonspecific amplification products, the "touchdown" method (16) of
thermal cycling was used with the following conditions: first cycle,
94 °C (2.5 min), 41 °C (1 min), and 72 °C (1 min); and second
cycle, 94 °C (45 s), 40 °C (1 min), and 72 °C (1 min). The
annealing temperature was then decreased by 1 °C each two cycles
until it reached 35 °C. 25 cycles were performed under these
conditions. A final cycle was then carried out at 94 °C (45 s),
35 °C (1 min), and 72 °C (10 min). Inverse PCR (17) was used to
extend the available PfGC
sequence after library screening (below) failed to isolate the full-length gene. Based on
Southern blot data, an AluI digest of genomic DNA (1 µg,
strain K1) was circularized with T4 DNA ligase, and an overlapping
fragment was obtained by inverse PCR using primers IPCR1 and IPCR2.
Construction of a Genomic DNA Library--
A
GEM-12 library
was constructed with P. falciparum (strain K1) genomic DNA
using a Promega kit according to the manufacturer's instructions.
Briefly, a Sau3a partial digest of genomic DNA was end-filled and ligated with blunt-ended XhoI cut
GEM-12
arms. After ligation, the DNA was packaged in vitro using a
Packagene Extract (Promega) and plated on Escherichia coli
strain LE392. The library (containing 2.7 × 105
clones) was screened with the original 220-bp PCR product using standard procedures (14), and a genomic clone (
1) containing part of
the PfGC
gene was isolated.
Construction and Screening of Vectorette
Libraries--
Vectorette libraries were constructed as described
previously (18) using 1 µg of genomic DNA (clone 3D7A) that had been digested with one of several restriction enzymes. This DNA (200 ng) was
ligated into blunt-ended Vectorette DNA (Cambridge Research Biochemicals). Based on known sequence and Southern blot information, PCR was performed using specific primers (AC1-AC9 for
PfGC
, pvec1-3 for PfGC
) and the Vectorette
I primer (Cambridge Research Biochemicals). With this procedure we were
able to obtain the remainder of the PfGC
coding sequence
and the cyclase-encoding domain of PfGC
. In the PCR
reactions, the polymerase was added to the tubes in the cycling block
when the reaction temperature was at least 80 °C. This "hot
start" and the use of annealing temperatures in the range
60-70 °C were important for the success of the reaction.
Oligonucleotides--
The following oligonucleotides were
used: DC1, 5'-GTATATAAAGTAGAAAC(A/T)AT(T/A)GG; MS2,
5'-(T/A)CC(A/G)AA(T/G)AA(A/G)CA(A/G)TA(T/A)C(T/G)(T/A)GGCAT; IPCR1,
5'-TTATGATCATCAATAAATAC; IPCR2, 5'-TTATTATTCATATCAGC; AC1, 5'-TGTATCACCATCGATTGTATTAAATG; AC2, 5'-CATAATAATTACTTGTATCACCATCG; AC3,
5'-ACGAGTAGGTTCAATACTGGCCAC; AC4, 5'-GGAAATAAAACTGCTTGAAATACTCC; AC5,
5'-GAATATGCTTCTGTTTAAATTCCTTTTTG; AC6, 5'-TTTTGAATATGCTTCTGTTTAAATTCC; AC7, 5'-GGCATTACTATTTTCTAAGGCAGC; AC8, 5'-ATGAGCAAGCATCATCATACATTC; AC9, 5'-TCTTCTTTGTCTTCATATGCATAGG; 5CAT,
5'-CGCGCGAATTCTCTACCTATTGTAAAGAATCA; 3CAT,
5'-CGCGCGAATTCCAAATTCGACTGGCGATCGTT; pvec1,
5'-ATCAATTCGTTTACTATATCTACTATC; pvec2, 5'-TTAACAGATCCAATCACACCACTG; and
pvec3, 5'-ACGTGTGGTTGTAATGTAGATACC (degenerate positions are
marked with slashes).
Nucleic Acid Analysis--
To isolate chromosome-sized DNA,
asexual blood stage parasites were first released from red blood cells
by saponin lysis and then washed in TSE buffer (20 mM Tris,
pH 8.0, 100 mM NaCl, 50 mM EDTA). The pellet
was resuspended in 9 volumes of TSE and then mixed with an equal volume
of 1.6% agarose in TSE and pipetted into a gel mold (Bio-Rad). The
agarose blocks (108-109 parasites/block) were
incubated in 1% sarcosinate, 0.5 M EDTA, pH 8.0, 2 mg
ml
1 proteinase K for 48 h at 50 °C and then
stored at 4 °C. Chromosome separations were performed with 1%
agarose gels using a contour-clamped homogeneous field electrophoresis
system (CHEF DRII, Bio-Rad). The gels were run in 0.5% TBE buffer at
100 V for 96 h with a pulse time of 360 s ramped to 800 s. Typically, hybridizations were performed at 42 °C in 6× SSC and
50% formamide with washes in 1× SSC at 50 °C. For lower stringency
experiments, hybridizations were at 50 °C in 5× SSC with washes in
2× SSC at room temperature. Northern blots were carried out using
standard conditions (15).
Production of Antibodies against the C2 Catalytic Domain of
PfGC
--
Oligonucleotide primers 5CAT and 3CAT were designed to
amplify the carboxyl-terminal region of PfGC
,
Ser3914-Leu4226), incorporating the C2
catalytic domain. EcoRI restriction sites were included in
the primers to facilitate insertion of the fragment in-frame with the
Schistosoma japonicum glutathione S-transferase gene of the pGEX1
T plasmid (Amersham Pharmacia Biotech). Expression of the fusion protein was induced in a 500-ml mid-log phase E. coli (strain JM109) culture (A600 = 0.4-0.5) by the addition of isopropyl-1-thio-
-D-galactopyranoside to a final
concentration of 1 mM for 2 h. Cells were resuspended
in phosphate-buffered saline /1% Triton X-100 and sonicated on ice.
The soluble fusion protein was bound to 2 ml of glutathione-agarose
(Sigma) on a Poly-Prep column (Bio-Rad) according to the
manufacturer's instructions. Bound protein was eluted by addition of 5 mM reduced glutathione and dissolved in 0.5 ml of normal
saline at a final concentration of 2 mg ml
1. This was
mixed with 0.5 ml of Ribi Adjuvant System (Sigma) resuspended in 1 ml
of normal saline. The mixture was homogenized by vortexing, and a New
Zealand White rabbit was immunized at six intradermal sites (50 µg
each), two intramuscular sites (200 µg each), and two subcutaneous
sites (100 µg each). Similar booster injections were given at
3-4-week intervals. Preimmune serum was taken prior to immunization.
Immunoelectron Microscopy--
Percoll-purified gametocytes that
had been stimulated to undergo gametogenesis were fixed for 30 min with
2% paraformaldehyde and 0.1% glutaraldehyde in phosphate-buffered
saline, dehydrated in ethanol, embedded in LR White (London Resin Co.),
and polymerized at 50 °C for 48 h. Ultrathin sections were
collected on piloform-coated nickel grids and incubated with primary
antibody and gold-conjugated secondary antibody as described previously
(19). The sections were silver enhanced using an Amersham Pharmacia
Biotech IntenSE M silver enhancement kit and then stained with a
saturated uranyl acetate solution in 30% methanol followed by Reynolds
lead citrate solution. The samples were analyzed with a JEOL 1200EX
transmission electron microscope at 80 kV and photographed using Agfa
Scienta EM film.
Sequence Analysis--
DNA sequencing was performed using an ABI
PRISM 377 DNA sequencer. The reactions were performed with a dye
terminator cycle sequencing Ready Reaction Kit (Perkin-Elmer).
Preliminary sequence data for P. falciparum chromosome 11 were obtained from the Institute for Genomic Research website.
Sequencing of chromosome 11 was part of the International Malaria
Genome Sequencing Project and was supported by an award from the NIAID,
National Institutes of Health. Sequence data for P. falciparum
chromosome 13 were obtained from the Sanger Center website. Sequencing
of P. falciparum chromosome 13 was accomplished as part of
the Malaria Genome Project with support by the Wellcome Trust.
Expression of Recombinant Proteins Corresponding to the PfGC
and PfGC
Catalytic Domains--
The cyclase catalytic domains of
both PfGC
(C1, Gly2998-Val3329, and C2,
Gln3956-Lys4163) and PfGC
(C1,
Val1533-Tyr1758, and C2,
Glu2946-Ala3122) and the catalytic domain of a
Trypanosoma cruzi AC (ADC-1,
Arg849-Lys1169) were cloned into pTrcHis C
(Invitrogen) to give hexahistidine amino-terminal fusion proteins.
Expression of the fusion proteins in E. coli (strain TP610,
AC-deficient) was induced at 30 °C by incubation with 0.1 mM isopropyl-1-thio-
-D-galactopyranoside for
1 h. Cultures were then lysed by sonication (six 10-s bursts at an
amplitude of 20 µm using an MSE Soniprep 150) in a solution containing 50 mM NaH2PO4, pH 8.0, 300 mM NaCl, 5 mM imidazole, 0.1% Triton
X-100, 10 mM
-mercaptoethanol, 1 mM
phenylmethylsulfonyl fluoride, 50 µg ml
1
1-chloro-3-tosylamido-7-amino-2-heptanone, and 1 mg ml
1
lysozyme). Lysates were cleared by centrifugation at 15,000 × g for 20 min at 4 °C. Proteins were affinity purified on
Ni2+-nitrilotriacetic acid Sepharose according to the
manufacturer's instructions (Qiagen).
Adenylyl/Guanylyl Cyclase Assays--
AC and GC activity was
assayed in reaction volumes of 40 µl. 30-µl aliquots of fusion
protein (2-5 µg) were added to 10 µl of 4× reaction buffer (40 mM Tris, pH 8.0, containing either ATP or GTP at 4 mM and 8 mM MgCl2 or
MnCl2) and incubated at 30 °C. Reactions were stopped by
addition of 10 µl of 0.2 M EDTA, pH 8.0, followed by
boiling for 2 min. For the t = 0 time points, EDTA was
added before the protein. cAMP or cGMP concentrations were measured in
96-well plates using a competition assay (20) with purified regulatory
subunit of beef heart cAMP-dependent protein kinase as the
cAMP-binding protein (PKA-R) or highly specific anti-cGMP antibodies as
the cGMP binding protein (21). Briefly, samples were mixed with 20 µl
of 0.4 mCi of [3H]cAMP (48 Ci mmol
1;
Amersham Pharmacia Biotech) or [3H]cGMP (14.8 Ci
mmol
1) per ml of assay buffer (4 mM EDTA in
150 mM sodium phosphate buffer, pH 7.5) and 20 µl of
PKA-R or cGMP antibody preparation. After incubation on ice for 90 min,
40 µl of activated charcoal (1.25 g of charcoal and 0.5 g of
bovine serum albumin in 25 ml of assay buffer) was added to adsorb
unbound [3H]cAMP or [3H]cGMP. Samples were
centrifuged at 3,000 × g for 15 min at 4 °C. 50 µl of supernatant was mixed with 100 µl of scintillation fluid, and
the radioactivity was measured (22). A standard curve was produced
with a linear range from 0-16 pmol cAMP/cGMP.
 |
RESULTS |
Isolation of PfGC
, a Gene That Encodes a Protein with Distinct
Cyclase and ATPase Domains--
Degenerate oligonucleotide primers
were designed based on conserved regions in the catalytic domains of
AC/GC from other species (see "Experimental Procedures"). Using
these, a 220-bp fragment was amplified by PCR from P. falciparum genomic DNA. Data base searches suggested that the
product was derived from a purine nucleotide cyclase gene homologue.
This fragment was used to screen a genomic DNA library, and a clone was
isolated. Sequence analysis of a 5.5-kilobase
BamHI-EcoRV fragment identified a 1.8-kilobase open reading frame (ORF) corresponding to the 3'-end of a cyclase-like gene, with a putative stop codon and adjacent 3' noncoding sequence. Inverse and Vectorette PCR techniques (see "Experimental
Procedures") were used to extend the sequence toward the 5'-end of
the gene. This generated an uninterrupted ORF of approximately 10 kilobases. A putative start codon was then identified following
searches of the Institute for Genomic Research P. falciparum
data base. Verification of the gene structure was obtained by
sequencing the corresponding region (Fig.
1), amplified from genomic DNA. In
addition the entire sequence of PfGC
has been confirmed following release of data from the Institute for Genomic Research data base, which became available during the preparation of this manuscript.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 1.
Organization of the PfGC
and PfGC genes.
RT/PCR was used to map introns in both genes (see "Experimental
Procedures"). The schematic shows the relative positions of the
introns in PfGC with respect to the ATPase and cyclase
domains. A schematic of the uninterrupted PfGC is also
shown. The sizes of each of the 12 introns that interrupt the
PfGC sequence and also the position with respect to the
amino acid sequence are shown. The nucleotide sequences that form the
intron splice sites are indicated; capital letters represent
exon sequence, and lowercase letters represent intron
sequence.
|
|
The nucleotide sequence of PfGC
comprises a single ORF of
12,678 bp (these sequence data have been submitted to the
GenBankTM data base under accession number AJ245435). The
A/T content (75.6%) and codon usage conform to that of all P. falciparum genes reported to date. The designated termination
codon (TAA) of PfGC
occurs in a position analogous to
that in mammalian-type AC (4, 23-25) and is followed immediately by an
extremely A/T-rich region (95%). Within the ORF, two regions of
unusually high A/T content were identified (nucleotides 7350-7530 and
nucleotides 9060-9450). To investigate the possibility of introns at
these positions and elsewhere in the gene, a series of RT/PCR reactions
were carried out. There were no differences in the sizes of the
products obtained from RNA (DNase I-treated) and genomic DNA (data not
shown). In negative controls where the reaction was performed in the
absence of RT, no products were amplified. Using this approach it was shown that PfGC
was uninterrupted by introns.
Analysis of the PfGC
sequence revealed an unexpected finding; the
gene had the potential to encode a bifunctional protein in which the
amino-terminal domain had high similarity to P-type ATPases (26), and
the carboxyl terminus was a structural homologue of G
protein-dependent adenylyl cyclases. The nucleotide
sequence adjacent to the putative start codon is aaaaATG, which is
similar to the consensus sequence upstream of many P. falciparum genes (27). The sequence immediately upstream of this
is preceded by a highly A/T-rich sequence interrupted by stop codons in
all three reading frames.
Isolation of PfGC
--
A P. falciparum
GEM-12
library was screened at low stringency with a probe corresponding to
the PfGC
C2 catalytic domain (see "Experimental
Procedures"). A clone containing 1.3 kilobase of sequence with
similarity to PfGC
and encompassing an in-frame stop
codon was isolated. This gene was designated PfGC
. The
remainder of the cyclase encoding region (an additional 2000 nucleotides) was obtained from Vectorette libraries (see
"Experimental Procedures"). Upstream, an additional open reading
frame with a high degree of similarity to P-type ATPases was
discovered. The sequence of this region was obtained from the P. falciparum genome project (Sanger Center). The cyclase and the
ATPase coding regions were found to be separated by 241 bp of A/T-rich
sequence. This was shown to be an intron, and both coding regions were
found to form a contiguous ORF. Sequence analysis of a series of RT/PCR
products obtained using primers specific to both the cyclase and ATPase domains demonstrated the presence of 12 introns in the
PfGC
sequence. These were all confined to the ATPase
encoding domain (Fig. 1). The fully spliced transcript has the
potential to encode a bifunctional protein of 3122 amino acids
(accession number AJ249165). The 5'-most exon contains an A/T-rich
sequence upstream of the designated start codon that has stop codons in
all three reading frames. Sequencing of RT/PCR products has confirmed
that this A/T-rich sequence forms part of the mature mRNA. The
predicted stop codon (position 9367) is located upstream of a region
with an extremely A/T-rich composition that has stop codons in all
three reading frames. The positions of the designated start and stop
codons are consistent with those found in other genes encoding similar P-type ATPases and cyclases, respectively. The sequence of the cyclase-encoding region has been confirmed by chromosome 13 sequence data that were released (Sanger Center) during preparation of this
manuscript. Using the Genestream Align global alignment program the
sequences of PfGC
and PfGC
were found to share 22% identity in
their cyclase domains and 19% in their ATPase domains.
Features of the Cyclase Domains--
The relatedness of both
PfGC
and PfGC
to GC/AC is concentrated in two regions
(PfGC
C1 Gly2999-Val3329;
PfC
C2, Gln3956-Lys4163;
PfGC
C1, Val1533-Tyr1758; and
PfGC
C2, Glu2946-Ala3122), which
have 26-33% sequence identity and 48-52% similarity (28) to the
corresponding regions of enzymes from diverse species. These
hydrophilic regions correspond to the positions of the catalytic domains. PfGC
C1 is characterized by the presence of a
long asparagine-rich stretch (amino acids
Asn3082-Asn3138; Fig.
2). Interestingly, the
aggregation-specific adenylyl cyclase (ACA) of the protozoan
Dictyostelium discoideum has a similar sequence insertion at
the same position within the C1 catalytic domain (29). There is a
second, shorter insertion in PfGC
C1 (Tyr3186-Thr3225; Fig. 2) that corresponds (in
terms of both position and size) to an insert found in all of the
trypanosomatid ACs sequenced to date. No such inserts are present in
the cyclase catalytic domains of PfGC
. Alignment of
PfGC
C1 with PfGC
C2 revealed 23% sequence
identity, whereas alignment of PfGC
C1 and
PfGC
C2 gave 34% identity.

View larger version (72K):
[in this window]
[in a new window]
|
Fig. 2.
Sequence alignment. Alignment of the
catalytic domains of PfGC and PfGC with those of the mammalian
soluble guanylyl cyclases GC 1 and GC 1
(49), the C1 domains of both mammalian type V adenylyl cyclase (VC1,
(50)) the Dictyostelium ACA (29), and the C2 domain of rat
type II adenylyl cyclase (IIC2). The known secondary structure of the
mammalian type V C1 domain (from a crystallographic study (36)) is
indicated by thick lines ( helix) and arrows
( sheet) beneath the sequence. The alignment illustrates the
reversal of the C1 and C2 domains of the Plasmodium proteins
in terms of key functional residues compared with the C1 and C2 domains
of mammalian adenylyl cyclases. The residues that determine purine
binding specificity are marked with a plus symbol;
green residues are indicative of adenine binding, and
red residues are indicative of guanine binding. Other
functionally important residues, determined by mutagenesis and
structural studies (discussed in the text) are indicated and have been
shown as follows. Light blue r, ribose binding; light
blue p, phosphate binding; dark blue m, divalent cation
binding. The amino acid residue numbers of each sequence are given on
the right. The alignment was produced using the PILEUP
program in the GCG package (51).
|
|
The cyclase catalytic domains of both PfGC
and PfGC
are each
preceded by highly hydrophobic regions that in membrane-associated mammalian ACs have been predicted to form two sets of six transmembrane domains. The PfGC
and PfGC
sequences are also compatible with this type of organization (Fig. 3).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 3.
A model of the proposed structure of
PfGC and PfGC .
The deduced amino acid sequences are each consistent with the presence
of two sets of six transmembrane regions in the cyclase domain and two
further sets of four and six transmembrane regions in the ATPase
domain. The cytoplasmic domains of the ATPase are based on a model
proposed for a muscle Ca2+-ATPase (31, 52).
|
|
Features of the ATPase Domains--
The putative ATPase domains of
both proteins conform to the P-type (or E1-E2) family of cation
transporting ATPases (30). The model for this family of enzymes
predicts 10 transmembrane domains arranged as a set of four toward the
amino terminus and a set of six near the carboxyl terminus. The amino
acid sequences of both PfGC
and PfGC
are consistent with this
type of structure (Fig. 3). For both PfGC
and PfGC
the
relatedness to P-type ATPases from diverse species is concentrated in
two regions and is summarized below. The amino-terminal domain of
PfGC
has 26-32% identity and 48-52% similarity over 250-300
amino acids; for the carboxyl terminus the figures are 28-30%
identity and 48-50% similarity. For PfGC
, the amino-terminal
domain has 23-25% identity and 43-46% similarity; for the carboxyl
terminus the figures are 21-23% identity and 46-48% similarity. The
membrane-spanning regions of the P-type ATPase domains are more highly
conserved than are those of the cyclase domains. This might be expected
given the potential functional significance of these transmembrane
regions. The consensus phosphorylation site of P-type ATPases (DKTGTLT)
is present in PfGC
(Asp756-Thr762) but not
in PfGC
. This signature sequence is involved in formation of an
aspartyl phosphate intermediate during ATP hydrolysis (31).
Expression and Subcellular Localization--
Southern analysis of
genomic DNA with a probe derived from the region of PfGC
corresponding to the C2 domain produced a hybridization pattern
consistent with a single copy gene (data not shown). In accordance with
this, when P. falciparum (clones 3D7A and T996) chromosomes
separated by CHEFE and transferred to nylon membranes were analyzed
(the probe corresponded to nucleotides 10,788-11,289), a single band
identified as chromosome 11 was detected (Fig.
4). PfGC
was localized to
chromosome 13. When northern blots of RNA derived from sexual and
asexual blood stage parasites were probed with PfGC
, a
transcript of approximately 12,000-14,000 nucleotides was detected
that was specific to the sexual blood stages (Fig. 4). The sexual stage
RNA had been prepared from Percoll-purified gametocytes (mainly stages
III-V), and the asexual stage RNA was prepared from an asynchronous
culture containing ring, trophozoite, and schizont stages. The same
blot was hybridized with a probe derived from the ATPase-encoding
domain of PfGC
(nucleic acids 5,901-6,630), and a band
of equal size was detected (Fig. 4). A northern blot was also
hybridized with a probe corresponding to the cyclase region of
PfGC
, and a slightly smaller transcript was identified
(Fig. 4). The northern blots were hybridized with other probes (data
not shown) to demonstrate both the integrity of the RNA preparations
and the equivalence of loading as described previously (32, 33). The
probes were derived from genes encoding sexual (Pfs16) and asexual
blood stage specific proteins (Msp1) and another (calmodulin) expressed
in similar amounts in both stages.

View larger version (80K):
[in this window]
[in a new window]
|
Fig. 4.
Chromosomal location and expression.
A, autoradiograph of a northern blot containing 10 µg of
total RNA from P. falciparum (clone 3D7A) erythrocytic
asexual (A) and sexual stage (S) parasites. The
four panels from left to right correspond to the
respective probes: PfGC (C2 domain), PfGC
(ATPase domain), PfGC (C2 domain), and msp1 (a
gene expressed specifically in asexual blood stage parasites). The size
of the PfGC gene transcript is indicated. Ethidium
staining of agarose gels was used to verify equivalent loading of
tracks and integrity of the RNA. B, CHEFE separation of
chromosomes from P. falciparum clones T996 (lanes
1, 3, and 5) and 3D7A (lanes 2,
4, and 6). Electrophoresis conditions were as
described in "Experimental Procedures." Lanes 1 and
2 show an ethidium bromide-stained agarose gel. After
transfer to a nylon membrane the DNA was hybridized with
PfGC (lanes 3 and 4) or
RESA-2 (lanes 5 and 6).
RESA-2 has been localized previously to chromosome 11 (53).
Similar results were obtained with the P. falciparum K1
strain(data not shown).
|
|
A rabbit polyclonal antiserum was raised to a recombinant protein
corresponding to the carboxyl terminus of PfGC
(amino acids Ser3914-Leu4226, incorporating the C2
catalytic domain) fused to glutathione S-transferase (see
"Experimental Procedures"). The serum was used in immunoelectron
microscopic examination of sections of red blood cells infected with
P. falciparum. Antibody binding was visualized by using a
colloidal gold-conjugated secondary antibody. Sexual erythrocytic stage
parasites (gametocytes) were strongly labeled in the
plasma/parasitophorous vacuole membrane region of the parasite (Fig.
5). Only very low levels of gold
particles were observed in the gametocyte cytoplasm. Little or no
labeling was present on uninfected red blood cells or asexual blood
stage parasites (Fig. 5). These sections also contained a small
proportion of developing gametes at various stages of emergence from
the surrounding red blood cell membrane and parasitophorous vacuole
membrane. No gold particles were observed in these forms. Preimmune
serum from the rabbit showed little or no labeling at the same
concentration as the test serum. An antiserum raised to a control
glutathione S-transferase fusion protein (derived from
Schistosoma mansoni) also gave no significant labeling.

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 5.
Subcellular localization of
PfGC . Sections of P. falciparum (clone 3D7A) erythrocytic stages were incubated with an
anti-PfGC polyclonal antibody (1:3000 dilution, "Experimental
Procedures"), and binding was visualized using a gold-conjugated
secondary antibody. Upper panel, gold particles indicative
of antibody binding are associated with the periphery of the gametocyte
encapsulated in a red blood cell. Only very low numbers of gold
particles can be detected in the cytoplasm. Middle panel, a
transverse section of a gametocyte showing similar labeling.
Lower panel, little or no binding of the antibody is
detectable with asexual erythrocytic stage parasites. This section
shows a schizont with levels of gold particles similar to that obtained
in all sections with preimmune serum (data not shown). Size
bars have been inserted in each panel.
|
|
Guanylyl Cyclase and Adenylyl Cyclase Enzyme Assays--
The
regions of PfGC
encoding both the C1
(Gly2999-Val3329) and C2
(Gln3956-Lys4163) domains and the regions of
PfGC
encoding both C1 (Val1533-Tyr1758) and
C2 (Glu2946-Ala3122) were expressed in
E. coli strain TP610 (AC-deficient) using an amino-terminal
hexahistidine tag system. The selection of these regions was based on
the scheme used for expression/crystallization of the rat type II AC C2
domain (25). Coomassie Blue-stained SDS-polyacrylamide gels and Western
blots (using a monoclonal antibody that reacts with a vector-derived
epitope at the amino terminus of fusion protein) showed distinct bands
at the predicted molecular masses (47 kDa for PfGC
C1, 32 kDa for PfGC
C2, 34 kDa for PfGC
C1, and 28 kDa for PfGC
C2) of the fusion proteins (data not shown).
The fusion proteins, purified by affinity chromatography on
Ni2+-nitrilotriacetic acid Sepharose columns, were tested
for AC or GC activities. Levels of cAMP/cGMP were measured by a
competition assay using 3H-labeled cAMP or cGMP (see
"Experimental Procedures").
The purified fusion proteins were first assayed for AC activity. No AC
activity was obtained using the
C1,
C2,
C1, or
C2 proteins
derived from these constructs either separately or in combination (Fig.
6). The catalytic domain of a
receptor-type AC (ADC-1) from T. cruzi was purified and
assayed in parallel. This fusion protein gave a high level of AC
activity which was maximized in the presence of Mn2+ ions
(34). We were also able to demonstrate functional complementation of
the AC-deficient E. coli strain (TP610) with the
trypanosome-derived construct, but this was not achievable with the
Plasmodium-derived constructs (data not shown).

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 6.
Adenylyl cyclase enzyme activity assays.
The graphs show time courses of cAMP production by the recombinant
catalytic domains derived from T. cruzi ADC-1 and PfGC
and PfGC . The data represent the means ± S.E. of three
independent experiments. 2-5 µg of affinity purified
His6-tagged fusion proteins were incubated at 30 °C for
the indicated time periods with 2 mM ATP and 4 mM Mn2+ and assayed for cAMP as described under
"Experimental Procedures." Control assays were performed on
proteins purified from cultures containing plasmid (pTrcHisC,
Invitrogen) with no insert. A, the catalytic domains of
PfGC ( C1 and C2) were assayed both separately and in
combination ( C1/ C2). B, the catalytic domains of
PfGC ( C1 and C2) were assayed separately and in combination
( C1/ C2). C, the catalytic domain of ADC-1 derived from
T. cruzi (34) was cloned into pTrcHisC, purified, assayed in
parallel, and used as an AC positive control.
|
|
We then tested the fusion proteins for GC activity. Fig.
7A shows that the C1 and C2
domains from the PfGC
gene showed no significant activity over
isolates from control bacteria either when tested individually or in
combination with each other. However, the fusion proteins derived from
the PfGC
gene showed moderate levels of activity when tested
individually, with
C1 being somewhat more active than
C2. When
used in combination, however, considerably elevated levels of activity
were obtained (Fig. 7B). Following a brief lag period, cGMP
synthesis increased rapidly over the first 10 min before decreasing. To
test whether the transient nature of this activity was due to the low
stability of the enzyme, we incubated the C1/C2 mixture at 30 °C for
25 min prior to the assay; this resulted in complete loss of activity
(Fig. 7C). Addition of forskolin, Ca2+, or
Ca2+/calmodulin to the reaction mixtures did not affect the
level of GC activity (data not shown). In all cases activity was
dependent on the presence of Mn2+ ions. If the divalent
cation was replaced with Mg2+, no activity could be
detected. Proteins from bacteria transformed with control pTrcHis
plasmid showed no activity.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 7.
Guanylyl cyclase enzyme activity assays.
The graphs show time courses of cGMP production by the recombinant
catalytic domains derived from PfGC and PfGC . The data represent
the means ± S.E. of three independent experiments. 2-5 µg of
affinity purified His6-tagged fusion proteins were
incubated at 30 °C for the indicated time periods with 2 mM GTP and 4 mM Mn2+ and assayed
for cGMP as described under "Experimental Procedures." Control
assays were performed on proteins purified from cultures containing
plasmid (pTrcHisC, Invitrogen) with no insert. A, the
catalytic domains of PfGC ( C1 and C2) were assayed both
separately and in combination ( C1/ C2). B, the
catalytic domains of PfGC ( C1 and C2) were assayed separately
and in combination ( C1/ C2). C, a further time course
experiment showing the effect of preincubation of C1/ C2 at
30 °C for 25 min.
|
|
 |
DISCUSSION |
We have isolated two genes from P. falciparum that
encode proteins with cyclase-like domains similar in structure to the
membrane-localized adenylyl cyclases of higher eukaryotes. Unusually,
the catalytic regions of at least one of these enzymes has guanylyl
cyclase activity. During the preparation of this manuscript, a GC with this type of structure was also described in Paramecium (9). An additional remarkable feature found in both the
Plasmodium and Paramecium proteins is that they
each have an amino-terminal domain with high similarity to P-type
ATPases in terms of sequence and predicted structure. GCs have hitherto
fallen into two subclasses: (i) membrane-associated receptor molecules
that form homodimers each with a single transmembrane domain and (ii)
soluble molecules that form heterodimers. PfGC
and PfGC
therefore
fall into a third subclass that is membrane-associated (with 12 putative membrane-spanning domains) with a pair of catalytic domains.
As in mammalian ACs, their activity is probably mediated by interaction
of the C1 and C2 domains.
Northern analysis of mRNA from the erythrocytic stages of P. falciparum also indicated that expression of both genes is
restricted to gametocytes (Fig. 4). Immunoelectron microscopy localized
PfGC
to the plasma/parasitophorous vacuole membrane region of this stage of the life cycle (Fig. 5). In red blood cells, malaria parasites
are surrounded by three membranes: the host cell membrane, the
parasitophorous vacuole membrane, and the parasite plasma membrane. The
latter two membranes are closely opposed, and it is not clear from our
electronmicrographs in which membrane PfGC
is located (Fig. 5).
However, it can be inferred from the sequence and by comparison with
other cyclases that both PfGC
and PfGC
are integral membrane
proteins. The parasites used for the immunoelectron microscopy study
had been stimulated to undergo gametogenesis (see "Experimental
Procedures"). The micrographs show parasites at various stages of
emergence from the red blood cell and parasitophorous vacuole
membranes. No labeling is associated with extracellular gametes,
suggesting that PfGC
has a pre-emergence role.
Structural Comparison of the PfGC
and PfGC
Catalytic Domains
with Those of Mammalian Adenylyl Cyclases--
The active site of
mammalian AC is formed by the interaction of the C1 and C2 domains
(35). Recent crystallographic and mutagenesis studies have given
insight into the nature of the catalytic site and have identified
residues involved in ATP binding (3, 25, 36-38). Based on these
studies, models for the analogous binding of GTP within the active site
of GC have been derived. From sequence alignment, it can be inferred
that the cyclase catalytic domains of both PfGC
and PfGC
are
different from those of mammalian G protein-dependent ACs
in that the C1 and C2 domains appear to be structurally reversed.
Several catalytically important residues that are present in the
mammalian C2 domain are found only in the C1 domain of the
Plasmodium molecules (Fig. 2). Likewise, mechanistically
important residues present in the C1 domain of the mammalian enzyme are
located in the C2 domains of PfGC
and PfGC
. For example, in
mammalian AC it has been predicted that Arg398 (type I AC),
which approaches the
phosphate of ATP, and Arg1011,
which interacts with the
phosphate, are localized in the C1 and C2
domains, respectively (36, 39). The equivalent residues in PfGC
(Arg4070 and Arg3268) and PfGC
(Arg3063 and Arg1696) are reversed with respect
to their location (Fig. 2). Similarly, three residues in mammalian AC
that interact with the ribose moiety of ATP, Thr315 (type I
C1), Asp354 (type I C1), and Asn1007 (type I
C2), are localized in the opposite catalytic domain in the
Plasmodium enzymes (Fig. 2). The equivalent positions in
PfGC
are Thr3973 (C2), Asp4019 (C2), and
Asn3264 (C1), and in PfGC
they are Thr2973
(C2), Asp3012 (C2), and Asn1692 (C1). In type I
mammalian AC, three negatively charged residues (Asp354,
Asp310, and Glu432) localized in the C1 domain
are thought to be involved in Mg2+ binding, an essential
requirement for enzyme activity (Refs. 3 and 39 and Fig. 2). The
corresponding negatively charged residues in PfGC
(Asp4019, Asp3975, and Glu4104) and
PfGC
(Asp3012, Asp2968, and
Glu3097) are all in the C2 domain.
Purine Binding Specificity--
The highly conserved regions of
mammalian-type ACs (C1a and C2a) are very similar to the corresponding
regions of the catalytic domains of GCs. Mutagenesis and
crystallographic studies have shown that a small number of residues are
involved in conferring the purine binding specificity of the two
enzymes (36, 37, 39, 40). Two separate studies have demonstrated that
the purine specificity of GC can be altered by changing key residues to
their counterparts in AC (E925K and C997D of retinal guanylyl cyclase 1, retGC-1 (39); R592Q of soluble GC
1; E473K and C541D
of soluble GC
1 (37)). This results in conversion to an
enzyme with an AC activity. These studies indicate a direct interaction
between Glu925 of GC and the N1 and N2 positions of the
guanine ring. In the C1 catalytic domains of both PfGC
and PfGC
,
the corresponding position is occupied by a glutamic acid residue
(Glu3058 and Glu1591, respectively) as would be
expected in a GC, and not lysine as in AC. However, the
Plasmodium enzymes are distinct from their mammalian
counterparts in that residues in the PfGC
and PfGC
positions that
correspond to the Cys997 (retGC-1), thought to be important
for guanine binding specificity, are both alanines (Ala3257
and Ala1785, respectively; Fig. 2). In the
Paramecium GC, the corresponding position is occupied by a
serine (9). It has been proposed (36) that the glutamic acid residue
(Glu473, GC
) is probably the most important residue for
determining GTP binding specificity. This was inferred from studies in
which mutated cyclases lacking a glutamic acid at this position were shown to have no GC activity. Modelling studies (36, 37, 39) have also
indicated that an arginine residue (Arg539, GC
, and
Arg592, GC
) is important for GTP binding. The arginine
residue at this position is conserved in GCs, and the corresponding
positions in the C2 domains of both PfGC
and PfGC
are also
occupied by arginines (Arg4089 and Arg3082, respectively).
Enzyme Activity of PfGC
and PfGC
--
Recombinant proteins
expressed in E. coli corresponding to the C1 and C2
catalytic domains of PfGC
and PfGC
were tested for both AC and GC
activity. No AC activity was detectable in any of the four
malaria-derived recombinant proteins. We were, however, able to
demonstrate GC activity in the C1 and C2 domains of PfGC
both
separately and in combination. The PfGC
C1/C2 mixture showed the
highest level of cGMP synthesis. No GC activity was detectable in the
C1 or C2 domains of PfGC
either separately or in combination. It is
not clear why activity was undetectable with PfGC
, but it is
possible that in the case of the C1 domain, the asparagine-rich insert
that interrupts the domain may interfere with catalysis in the context
of this construct. When the respective C1 and C2 domains of the PfGC
and PfGC
were mixed with their heterologous partner (
C1/
C2 and
C1/
C2), there was evidence of some inhibition of activity of the
PfGC
domains (data not shown). A similar phenomenon of inhibition
between two ACs from Leishmania donovani has been reported
(41). In this case activity could also be detected in only one of the cyclases.
In the present study, we have demonstrated that although the C1 and C2
domains of PfGC
synergize to synthesize cGMP, the individual domains
also display activity (Fig. 7). Basal levels of AC activity have been
reported in both the C1 and C2 catalytic domains of mammalian AC in the
absence of specific activators (35). By analogy, the GC activity that
we have demonstrated in this study probably represents only basal
activity, because no activator has yet been identified. It is also
possible that other parts of the PfGC
and PfGC
proteins, not
included in the expressed fusion proteins, may have a regulatory role
and could be required for optimal activity.
The Association of Ca2+ and Guanylyl Cyclase
Activity--
Of the P-type ATPases, it is the Ca2+ pump
isoforms that have the highest similarity with the amino-terminal
domains of PfGC
and PfGC
. This suggests the possibility that
Ca2+ may be involved in the regulation of GC activity in
P. falciparum. Ca2+-dependent GC
activity has been demonstrated in a number of systems. For example, in
Paramecium there is a causal association between Ca2+ influx and an increase in intracellular cGMP levels
(reviewed in Ref. 42). This Ca2+-dependent cGMP
production is vital to the control of ciliary movement and locomotion.
In mammals, retinal GC activity, involved in light activation of
photoreceptors, is closely associated with Ca2+ levels, and
it has been shown that specific calcium-binding proteins regulate this
activity (Ref. 43; reviewed in Ref. 6). The intimate association of GC
activity with a putative Ca2+ pump in PfGC
and PfGC
is intriguing in light of some earlier work on Plasmodium
(2). This has implicated both Ca2+ and cGMP in the control
of exflagellation. Ca2+ antagonists (but not
Ca2+ channel inhibitors) strongly inhibit exflagellation,
whereas it is enhanced by cGMP and agents that increase levels of cGMP. It will therefore be of considerable interest to investigate whether the linkage of GC activity with a putative Ca2+ pump ATPase
in a single polypeptide is of functional significance.
Evolutionary Significance--
It can be presumed that the
"progenitor PfGC" protein arose from the fusion of two genes, one
encoding a P-type ATPase and the second encoding a cyclase. This is not
without precedence. There are at least two other examples in
Plasmodium of bifunctional proteins that occur as distinct
molecules in other organisms. These are the dihydrofolate
reductase-thymidylate synthase (44, 45) and dihydropteroate
synthetase/pyrophosphokinase (46, 47). The most likely scenario is that
the initial fusion event was followed by gene duplication creating two
copies that diverged to become PfGC
and
PfGC
. The fusion event appears to have occurred in a
common ancestor of Plasmodium and Paramecium.
This is consistent with classification of the ciliates with
apicomplexans and dinoflagellates in the Alveolata (9, 48).
An additional feature of the two Plasmodium genes is the
presence of 12 introns in the ATPase encoding domain of
PfGC
, compared with none in the corresponding region of
PfGC
(Fig. 1). From a functional viewpoint, it is not
immediately obvious why PfGC
and PfGC
, two proteins with the same
potential activity, should be expressed during the sexual stages of the
life cycle. One possibility is that they are expressed differentially
during this complex life cycle phase. Another is that they are
co-expressed but that they respond to different activators. A greater
understanding of this signaling pathway and the manner in which it is
regulated is of importance, particularly in the context of novel
chemotherapeutic targets. The structural differences that we have
identified between Plasmodium GC and its mammalian
counterparts may be exploitable for the development of drugs capable of
blocking transmission of malaria. The recent development of genetic
manipulation techniques applicable to malaria parasites will allow this
possibility to be explored further.
 |
ACKNOWLEDGEMENTS |
We thank Maria McCrossan for excellent
technical assistance with the immunoelectron microscopy and Quentin
Bickle for the gift of an anti-schistosome/glutathione
S-transferase antibody and for performing immunizations. We
are grateful to Antoine Danchin (Institut Pasteur, Paris, France) for
the kind gift of E. coli strain TP610 and for helpful
discussions. We also acknowledge James H. Hurley (National Institutes
of Health) for helpful discussions concerning purine binding
specificity. Thanks also to Claire Swales and Shane Wilkinson for
discussions relating to this work and for help with production of the manuscript.
 |
FOOTNOTES |
*
This work was supported by a project grant from the Wellcome
Trust (to D. A. B. and J. M. K.), a Wellcome Trust
University Award (to D. A. B.), and a WHO/UNDP/World Bank
special program award (to D. C. W.). Preliminary sequence
data for P. falciparum chromosome 11 were obtained from the
Insitute for Genomic Research website. Sequencing of chromosome 11 was
part of the International Malaria Genome Sequencing Project and was
supported by award from the NIAID, National Institutes of Health.
Sequence data for P. falciparum chromosome 13 were obtained
from the Sanger Center website. Sequencing of P. falciparum
chromosome 13 was accomplished as part of the Malaria Genome Project
with support by the Wellcome Trust.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
b
These authors contributed equally to this work.
c
Present address: Malaria Program, Naval
Medical Research Center, 503 Robert Grant Ave., Silver Spring, MD
20910-7500.
d
Supported by the U.S. Navy and an Overeseas
Research Student award.
e
Supported in part by a grant from the Sir
Halley Stewart Trust.
f
Supported by a Wellcome Trust Prize
Studentship and an Overseas Research Student award.
g
Supported by United Kingdom Public Health
Laboratory Service.
j
Present address: ICRF Laboratories, Inst. of
Molecular Medicine, John Radcliffe Hospital, University of Oxford,
Oxford, OX3 9DS, UK.
k
To whom correspondence should be addressed.
Fax: 44-207-636-8739; E-mail: david.baker@lshtm.ac.uk.
Published, JBC Papers in Press, March 28, 2000, DOI 10.1074/jbc.M001021200
 |
ABBREVIATIONS |
The abbreviations used are:
AC, adenylyl
cyclase;
GC, guanylyl cyclase;
PKA, cAMP-dependent protein
kinase;
PCR, polymerase chain reaction;
bp, base pair(s);
ORF, open
reading frame;
RT, reverse transcription.
 |
REFERENCES |
| 1.
|
Bilker, O.,
Lindo, V.,
Panico, M.,
Etienne, A. E.,
Paxton, T.,
Dell, A.,
Rodgers, M.,
Sinden, R. E.,
and Morris, H. R.
(1998)
Nature
392,
289-292
|
| 2.
|
Kawamoto, F.,
Alejo-Blanco, R.,
Fleck, S. L.,
Kawamoto, Y.,
and Sinden, R. E.
(1990)
Mol. Biochem. Parasitol.
42,
101-108
|
| 3.
|
Sunahara, R. K.,
Dessauer, C. W.,
and Gilman, A. G.
(1996)
Annu. Rev. Pharmacol. Toxicol.
36,
461-480
|
| 4.
|
Krupinsky, J.,
Coussen, F.,
Bakalyar, H. A.,
Tang, W.-J.,
Feinstein, P. G.,
Orth, K.,
Slaughter, C.,
Reed, R. R.,
and Gilman, A. G.
(1989)
Science
244,
1558-1564
|
| 5.
|
Chinkers, M.,
and Garbers, D. L.
(1991)
Annu. Rev. Biochem.
60,
553-575
|
| 6.
|
Garbers, D. L.,
and Lowe, D. G.
(1994)
J. Biol. Chem.
269,
30741-30744
|
| 7.
|
Janssens, P. M.,
and de Jong, C. C.
(1988)
Biochem. Biophys. Res. Commun.
150,
405-411
|
| 8.
|
Schultz, J. E.,
and Klumpp, S.
(1991)
Methods Enzymol.
195,
466-474
|
| 9.
|
Linder, J. U.,
Engel, P.,
Reimer, A.,
Krüger, T.,
Plattner, H.,
Schultz, A.,
and Schultz, J. E.
(1999)
EMBO
18,
4222-4232
|
| 10.
|
Ward, G. E.,
Moy, G. W.,
and Vacquier, V. D.
(1986)
Adv. Exp. Med. Biol.
207,
359-382
|
| 11.
|
Walliker, D.,
Quakyi, I. A.,
Wellems, T. E.,
McCutchan, T. F.,
Szarfman, A.,
London,
Corcoran, L. M.,
Burkot, T. R.,
and Carter, R.
(1987)
Science
236,
1661-1666
|
| 12.
|
Thaithong, S.,
Beal, G. H.,
Fenton, B.,
McBride, J.,
Rosario, V.,
Walker, A.,
and Walliker, D.
(1984)
Trans. Roy. Soc. Trop. Med. Hyg.
78,
242-245
|
| 13.
|
Harte, P. G.,
Rogers, N. C.,
and Targett, G. A. T.
(1985)
Immunology
56,
1-7
|
| 14.
|
Sambrook, J.,
Fritsch, E. F.,
and Maniatis, T.
(1989)
Molecular Cloning: A Laboratory Manual
, 2nd Ed.
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 15.
|
Robson, K. J. H.,
and Jennings, M. W.
(1991)
Mol. Biochem. Parasitol.
46,
19-34
|
| 16.
|
Don, R. H.,
Cox, P. T.,
Wainwright, B. J.,
Baker, K.,
and Mattick, J. S.
(1991)
Nucleic Acids Res.
19,
4008
|
| 17.
|
Triglia, T.,
Peterson, M. G.,
and Kemp, D. J.
(1988)
Nucleic Acids Res.
16,
8186
|
| 18.
|
Li, J.-L.,
Robson, K. J. H.,
Targett, G. A. T.,
and Baker, D. A.
(1996)
Eur. J. Biochem.
241,
805-813
|
| 19.
|
Baker, D. A.,
Daramola, O. O.,
McCrossan, M. V.,
Harmer, J.,
and Targett, G. A. T.
(1994)
Parasitology
108,
129-137
|
| 20.
|
Gilman, A. G.
(1972)
Adv. Cyclic Nucleotide Res.
2,
9-24
|
| 21.
|
Schulkes, C. C. G. M.,
Schoen, C. D.,
Arents, J. C.,
and Van Driel, R.
(1992)
Biochim. Biophys. Acta
1135,
73-78
|
| 22.
|
van Es, S.,
Virdy, K. J.,
Pitt, G. S.,
Meima, M.,
Sands, T. W.,
Devreotes, P. N.,
Cotter, D. A.,
and Schaap, P.
(1996)
J. Biol. Chem.
271,
23623-23625
|
| 23.
|
Bakalyar, H. A.,
and Reed, R. R.
(1990)
Science
250,
1403-1406
|
| 24.
|
Defer, N.,
Marinx, O.,
Stengel, D.,
Danisova, A.,
Iourgenko, V.,
Matsuoka, I.,
Caput, D.,
and Hanoune, J.
(1994)
FEBS Lett.
351,
109-113
|
| 25.
|
Zhang, G.,
Ruoho, A. E.,
and Hurley, J. H.
(1997)
Nature
386,
247-253
|
| 26.
|
Ripmaster, T. L.,
Vaughn, G. P.,
and Woodford, J. L., Jr.
(1993)
Mol. Cell. Biol.
13,
7901-7912
|
| 27.
|
Saul, A.,
and Battistutta, D.
(1990)
Mol. Biochem. Parasitol.
42,
55-62
|
| 28.
|
Altschul, S. F.,
Gish, W.,
Myers, E. W.,
and Lipman, D. J.
(1990)
J. Mol. Biol.
215,
403-410
|
| 29.
|
Pitt, G. S.,
Milona, N.,
Borleis, J.,
Lin, K. C.,
Reed, R. R.,
and Devreotes, P. N.
(1992)
Cell
69,
305-315
|
| 30.
|
Jencks, W. P.
(1992)
Ann. N. Y. Acad. Sci.
671,
49-56
|
| 31.
|
MacLennan, D. H.,
Brandl, C. J.,
Korczak, B.,
and Green, N. M.
(1985)
Nature
316,
696-700
|
| 32.
|
Li, J.-L.,
and Baker, D. A.
(1997)
Eur. J. Biochem
249,
98-106
|
| 33.
|
Li, J.-L.,
and Baker, D. A.
(1998)
Mol. Biochem. Parasitol.
95,
287-295
|
| 34.
|
Taylor, M. C.,
Muhia, D. K.,
Baker, D. A.,
Mondragon, A.,
Schaap, P.,
and Kelly, J. M.
(1999)
Mol. Biochem. Parasitol.
104,
205-217
|
| 35.
|
Tang, W.-J.,
and Gilman, A. G.
(1995)
Science
268,
1769-1772
|
| 36.
|
Tes |